Zacks Investment ResearchFri, 27 Mar 2026 16:31:10 GMTWhy Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?SRPT+1.65%
Zacks Investment ResearchThu, 26 Mar 2026 18:15:33 GMTSRPT Stock Surges on Promising Early Results From siRNA ProgramsSRPT+1.65%
Zacks Investment ResearchThu, 26 Mar 2026 14:01:25 GMTSarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?SRPT+1.65%
Seeking AlphaWed, 25 Mar 2026 21:35:55 GMTSarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 TranscriptSRPT+1.65%
24/7 Wall StreetWed, 25 Mar 2026 13:44:47 GMTSarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?SRPT+1.65%
Zacks Investment ResearchFri, 20 Mar 2026 15:50:47 GMTSarepta Plans FDA Filings Seeking Full Approval for Two DMD TherapiesSRPT+1.65%
BenzingaThu, 19 Mar 2026 15:51:06 GMTSarepta To Request FDA For Traditional Approvals For Duchenne DrugsSRPT+1.65%
Zacks Investment ResearchTue, 17 Mar 2026 15:35:28 GMTSRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety StudySRPT+1.65%
Seeking AlphaTue, 03 Mar 2026 22:32:18 GMTSarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSRPT+1.65%
Zacks Investment ResearchThu, 26 Feb 2026 16:32:08 GMTSarepta Q4 Loss Wider Than Expected, Sales Beat EstimatesSRPT+1.65%
Zacks Investment ResearchThu, 26 Feb 2026 15:31:10 GMTCompared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key MetricsSRPT+1.65%
Seeking AlphaThu, 26 Feb 2026 01:27:48 GMTSarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call TranscriptSRPT+1.65%
Zacks Investment ResearchWed, 18 Feb 2026 16:05:30 GMTSarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?SRPT+1.65%
Zacks Investment ResearchTue, 27 Jan 2026 16:50:37 GMTSRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMDSRPT+1.65%
Seeking AlphaMon, 26 Jan 2026 18:32:20 GMTSarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy TranscriptSRPT+1.65%
Zacks Investment ResearchMon, 26 Jan 2026 18:00:20 GMTSarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?SRPT+1.65%
Investors Business DailyMon, 26 Jan 2026 14:47:02 GMTSarepta Pops On Elevidys Data; But Will It Save The Embattled Gene Therapy?SRPT+1.65%
BarronsMon, 26 Jan 2026 13:53:00 GMTSarepta Stock Rises on Positive 3-Year Study Results for ElevidysSRPT+1.65%
